Crinetics Pharmaceuticals, Inc. (CRNX) Stock

Crinetics Pharmaceuticals, Inc. (CRNX) is a Healthcare stock trading at $35.90 (as of 2026-06-18), with a market capitalization of $3.75B and a trailing P/E of -6.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Crinetics Pharmaceuticals, Inc. is a clinical-stage company developing therapies for rare endocrine disorders and endocrine-related tumors. It advances candidates including Paltusotine (an oral somatostatin receptor type 2 agonist) for acromegaly and other endocrine conditions, and also studies CRN04777 and CRN04894 for additional endocrine diseases in early-stage clinical trials.

Valuation — source: SEC EDGAR (first-party)
Price	$35.90
Market Cap	$3.75B
P/E Ratio	-6.7
EV / EBITDA	-6.5
Price / Book	2.84
Price / Sales	201.15
DCF Value (model)	$-61.41
DCF Upside vs Price	-271.1%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$7.70M
Net Margin	-6046.2%
Return on Equity	-38.8%
Current Ratio	18.60
Revenue Growth (YoY)	2873.4%
EPS Growth (YoY)	18.3%
FCF Growth (YoY)	40.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	14.57 (safe)

Valuation vs Sector & Industry
Stock P/E	-6.7
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-132.0%
vs Industry	-138.9%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	FMR LLC ($572.40M)
Institutional Holders Tracked	10
Congressional Trades (recent)	5

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	R. Scott Struthers
Employees	437
Country	US
IPO Date	2018-07-18

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.